Atlas Trials

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

2 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

RecordFirmDate
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (NCT07252232)Revolution Medicines, Inc.2025-12-15
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (NCT03727880)Lei Zheng2019-06-04

Track Resectable Pancreatic Ductal Adenocarcinoma (PDAC) automatically

Every clearance here is in the API, with alerts when new ones post.